secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001193125-23-046651
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir appoints Derek Adams to board; Ansbert Gadicke retires
--------------------------------------------------------------

- Derek Adams, Ph.D. appointed to Board effective March 1, 2023, filling vacancy from Ansbert Gadicke's retirement.
- Dr. Adams brings over 20 years of experience in manufacturing biologic and gene therapies; currently CEO of Stellular Bio.
- Ansbert Gadicke, M.D. retires from board effective February 28, 2023; no disagreement with company.
- AlloVir is a late-clinical stage allogeneic T cell immunotherapy company with three ongoing Phase 3 studies for posoleucel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312523046651/0001193125-23-046651-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312523046651/d317019d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-046651

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer